Molina MFJ

Idioma: Español
Referencias bibliográficas: 20
Paginas: 100-106
Archivo PDF: 103.26 Kb.

RESUMEN

Los transportadores de oxígeno pueden ser agrupados en dos categorías: Soluciones basadas en hemoglobina y emulsiones basadas en perfluoroquímicos. La transfusión de eritrocitos alogénicos representa un recurso limitado y está asociada con eventos adversos como reacciones de transfusión aguda, transmisión de enfermedades infecciosas, inmunosupresión e infecciones postoperatorias. Aunque la “sangre artificial” no es una realidad clínica, algunos “transportadores artificiales de oxígeno” están en un estadio clínico en desarrollo.

REFERENCIAS (EN ESTE ARTÍCULO)

1. SCOTT MG, KUCIK DF, GOODNOUGH LW, MONK TG: Blood substitutes: Evolution and future applications. Clinical Chemistry 1997; 43(9): 1724-1731.

2. TREMBLAY LN, RIZOLI SB, BRENNEMAN FD: Advance in fluid resuscitation of hemorrhagic shock. Canadian Journal of Surgery 2001; 44(3): 172-179.

3. WINSLOW RM: Blood substitutes: Refocusing and elusive goal. Br J Hematol 2000; 111: 387-396.

4. DOOD RY: Current viral risk of blood and blood products. Ann Med 2000; 32(7): 469-474.

5. KLEIN HJ: The prospects for red-cell substitutes. New Engl J Med 2000; 342(22): 1666-1668.

6. SARTESCHI LM, SAGRIPANTI A, CARPI A, MECHINIFABRIS F: Rationale for development of red-cell substitutes and status of the research. Internal Med. 2001; 9: 36-44.

7. HEISS MM, FRAUNBERGER P, DELANOFF C, STETS R, ET AL: Modulation of immune response by blood transfusion: evidence for a differential effect of allogenic o autologous blood in colorectal cancer surgery. Shock 1997; 8(6): 402-408.

8. VAMVAKAS EC: Allogenic blood transfusion as a risk factor for the subsequent development of non-Hodgkin’s lymphoma. Transfus Med Rev 2000; 14(3): 258-268.

9. CREMIUX PY, BARRETT B, ANDERSON K, SLAVIN MB: Cost of outpatient blood transfusion in cancer patient. J Clin Oncol 2000; 18: 2755-2761.

10. SPAHN DR, LEONE BJ, REVES JG, PASCH T. Cardiovascular and coronary physiology of acute isovolemic hemodilution: review of nonoxygen-carry and oxygen carrying solutions. Anesth Analg 1994; 78: 1000-1021.

11. ZELLEN G, OFFNER PJ, MOORE EE, BLACKWELL J: Age of transfused blood is an independent risk factor for postinjury multiple organ failure. Am J Surg 1999; 178: 570-572.

12. JOHNSON JL, MOORE EE, OFFNER PJ, PATRICK DA, TAMURA DY, ET AL: Resuscitation with a blood substitute abrogates pathologic postinjury neutrophil cytotoxic function. J Trauma 2001; 50: 449-456.

13. SILLIMAN CC, VOELKEL NF, ALLARD JD, ELZI DJ: Plasma and lipids from stored packed blood cells cause acute lung injury in animal model. J Clin Invest 1998; 101(7): 1458-1467.

14. FUJIHARA M, TAKAHASHI TA, OGISO C, HOSODA M, ICKEBUCHI K: Generation of interleukin 8 in stored apheresis platelet concentrates and the preventive effect of prestorage ultraviolet B radiation. Transfusion 1997; 37: 468-475.

15. SILLIMAN CC, CLAY KL, THURMAN GW, JOHNSON CA, AMBRUSO DR: Partial characterization of lipids that develop during the routine storage of blood and prime the neutrophil NADPH oxidase. J Lab Clin Med 1994; 124: 684-694.

16. LIU L, MUL FP, KUIJPERS TW: Neutrophil transmigration across monolayers of endothelial cells and airway epithelial cell is regulated by different mechanisms. Ann N Y Acad Sci 1996; 796: 21-9.

17. SPAHN DR: Blood substitutes. Artificial oxygen carriers: perfluorocarbon emulsions. Crit Care 1999; 3: R93-R97.

18. IVANITSKY GR: Biophysics at the turn of the millennium: perflurorcarbon media and gas-transporting blood substitutes. Biophysics 2001; 46: 1-31.

19. MORTON JD, PORTER E, YABUKI H, NATH R, ROCKWELL S: Effects of a perfluorochemical emulsion on the response of BA1112 rat 1992 rhabdomyosarcomas to continuous low-dose-rate irradiation. Radiat Res 1990; 124: 178-82.

20. ECKMANN DM, DIAMOND SL: Surfactants attenuate gas embolism-induced thrombin production. Anesthesiology 2004; 100: 77-84.